In vitro monoamine oxidase A and B inhibitory activity and molecular docking simulations of fucoxanthin

Fisheries Science

Volumn 83, Issue 1, 2017, Pages 123-132

  Jung, Hyun Ah ^a   Roy, Anupom ^b   Choi, Jae Sue ^b  

^a Chonbuk National University   (South Korea)

^b Pukyong National University   (South Korea)

Author keywords

Docking; Fucoxanthin; Kinetic; Monoamine oxidase; Parkinson s disease

Indexed keywords

EID: 84994752037     PISSN: 09199268     EISSN: 14442906     Source Type: Journal    
DOI: 10.1007/s12562-016-1036-2     Document Type: Article

References (43)

1. Abdullah R, Basak I, Patil KS, Alves G, Larsen JP, Moller G (2015) Parkinson’s disease and age: the obvious but largely unexplored link. Exp Gerontol 68:33–38
2. Lin RD, Hou WC, Yen KY, Lee MH (2003) Inhibition of monoamine oxidase B (MAO-B) by Chinese herbal medicines. Phytomedicine 10:650–656
3. Bach AW, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan SW, Seeburg PH, Shih JC (1988) cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci USA 85:4934–4938
4. Sturza A, Leisegang MS, Babelova A, Schroder K, Benkhoff S, Loot AE, Fleming I, Schulz R, Muntean DM, Brandes RP (2013) Monoamine oxidases are mediators of endothelial dysfunction in the mouse aorta. Hypertension 62:140–146
5. Friedman A, Arosio P, Finazzi D, Koziorowski D, Galazka-Friedman J (2011) Ferritin as an important player in neurodegeneration. Parkinsonism Relat Disord 17:423–430
6. Schwartz TL (2013) A neuroscientific update on monoamine oxidase and its inhibitors. CNS Spectr 18:25–32
7. Lum CT, Stahl SM (2012) Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression. CNS Spectr 17:107–120
8. Fernandez HH, Chen JJ (2007) Monoamine oxidase-B inhibition in the treatment of Parkinson’s disease. Pharmacotherapy 27:174S–185S
9. Youdim MB, Riederer PF (2007) Monoamine oxidase A and B inhibitors in Parkinson’s disease. Handb Clin Neurol 84:93–120
10. Findberg JP, Gillman K (2011) Selective inhibitors of monoamine oxidase type B and the “cheese effect”. Int Rev Neurobiol 100:169–190
11. Shulman KI, Herrmann N, Walker SE (2013) Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs 27:789–797
12. Kolla NJ, Attard S, Craig G, Blackwood N, Hodgins S (2014) Monoamine oxidase-A alleles in violent offenders with antisocial personality disorder: high activity associated with proactive aggression. Crim Behav Ment Health 24:368–372
13. Culpepper L (2013). Reducing the burden of difficult-to-treat major depressive disorder: revising monoamine oxidase inhibitor therapy. Prim Care Companion CNS Disord 15: PCC. 13r01515
14. Stahl SM, Felker A (2008) Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr 13:855–870
15. Rojas RJ, Edmondson DE, Almos T, Scott R, Massari ME (2015) Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques. Bioorg Med Chem 23:770–778
16. Gerlach M, Riederer R, Youdim BH (1992) The molecular pharmacology of L-deprenyl. Eur J Pharmacol 226:97–108
17. Hubalek F, Binda C, Li M, Herzig Y, Sterling J, Youdim MB, Mattevi A, Edmondson DE (2004) Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues. J Med Chem 47:1760–1766
18. Binda C, Hubalek M, Li M, Herzig Y, Sterling J, Edmondson DE, Mattevi A (2004) Crystal structures of monoamine oxidase B in complex with for inhibitors of the N-propargylaminoindan class. J Med Chem 47:1767–1774
19. Prins LH, Petzer JP, Malan SF (2010) Inhibition of monoamine oxidase by indole and benzofuran derivatives. Eur J Med Chem 45:4458–4466
20. Tipton KF, Boyce S, O’Sullivan J, Davey GP, Healy J (2004) Monoamine oxidases: certainties and uncertainties. Curr Med Chem 11:1965–1982
21. Chuyen VH, Eun JB (2015) Marine carotenoids: bioactivities and potential benefits to human health. Crit Rev Food Sci Nutr. doi:10.1080/10408398.2015.1063477
22. Gammone MA, Riccioni G, D’Orazio N (2015) Marine carotenoids against oxidative stress: effects on human health. Mar Drugs 13:6226–6246
23. Matsuno T (2001) Aquatic animal carotenoids. Fish Sci 67:771–783
24. Jung HA, Islam MN, Lee CM, Jeong HO, Chung HY, Woo HC, Choi JS (2012) Promising antidiabetic potential of fucoxanthin isolated from the edible brown algae Eisenia bicyclis and Undaria pinnatifida. Fish Sci 78:1321–1329
25. Peng J, Yuan JP, Wu CF, Wang JH (2011) Fucoxanthin, a marine carotenoid presents in brown seaweeds and diatoms: metabolism and bioactivities relevant to human health. Mar Drugs 9:1806–1828
26. Terasaki M, Hirose A, Narayan B, Baba Y, Kawagoe C, Yasui H, Saga N, Hosokawa M, Miyashita K (2009) Evaluation of recoverable functional lipid components of several brown seaweeds (phaeophyta) from Japan with special reference to fucoxanthin and fucosterol contents (1). J Phycol 45:974–980
27. Valley MP, Zhou W, Hawkins EM, Shultz J, Cali JJ, Worzella T, Bernad L, Good T, Good D, Riss TL, Klaubert DH, Wood KV (2006) A bioluminescent assay for monoamine oxidase activity. Anal Biochem 359:238–246
28. Goodsell DS, Morris GM, Olson AJ (1996) Automated docking of flexible ligands: applications of AutoDock. J Mol Recognit 9:1–5
29. Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267:727–748
30. Rarey M, Kramer B, Lengauer T, Klebe G (1996) A fast flexible docking method using an incremental construction algorithm. J Mol Biol 261:470–489
31. Tomi IHR, Al-Daraji AHR, Abdula AM, Al-Marjani MF (2013) Synthesis, antimicrobial and docking study of three novel 2, 4, 5-triarylimidazole derivatives. J Saudi Chem Soc. doi:10.1016/j.jscs.2013.03.004
32. Laskowski RA, Swindells MB (2011) LigPlot+: multiple ligand–protein interaction diagrams for drug discovery. J Chem Inf Model 51:2778–2786
33. Novaroli L, Daina A, Favre E, Bravo J, Carotti A, Leonetti F, Catto M, Carrupt PA, Reist M (2006) Impact of species-dependent differences on screening, design, and development of MAO-B inhibitors. J Med Chem 49:6264–6272
34. Asai A, Sugawara T, Ono H, Nagao A (2004) Biotransformation of fucoxanthinol into amarouciaxanthin A in mice and HepG2 cells: formation and cytotoxicity of fucoxanthin metabolites. Drug Metab Dispos 32:205–211
35. Hashimoto T, Ozaki Y, Taminato M, Das SK, Mizuno M, Yoshimura K, Maoka T, Kanazawa K (2009) The distribution and accumulation of fucoxanthin and its metabolites after oral administration in mice. Br J Nutr 102:242–248
36. Choi JH, Kim NH, Kim SJ, Lee HJ, Kim S (2016) Fucoxanthin inhibits the inflammation response in paw edema model through suppressing MAPKs, Akt, and NFκB. J Biochem Mol Toxicol 30:111–119
37. Zhao X, Zhang S, An C, Zhang H, Sun Y, Li Y, Pu X (2015) Neuroprotective effect of fucoxanthin on β-amyloid-induced cell death. J Chin Pharm Sci 24:467–474
38. Hwang O (2013) Role of oxidative stress in Parkinson’s disease. Exp Neurobiol 22:11–17
39. Maeda H, Hosokawa M, Sashima T, Takahashi N, Kawada T, Miyashita K (2006) Fucoxanthin and its metabolite, fucoxanthinol, suppress adipocyte differentiation in 3T3-L1 cells. Int J Mol Med 18:147–152
40. Hosokawa M, Kudo M, Maeda H, Kohno H, Tanaka T, Miyashita K (2004) Fucoxanthin induces apoptosis and enhances the antiproliferative effect of the PPARgamma ligand, troglitazone, on colon cancer cells. Biochim Biophys Acta 1675:113–119
41. Martin HL, Mounsey RB, Mustafa S, Sathe K, Teismann P (2012) Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for antioxidant protection in a model of Parkinson’s disease. Exp Neurol 235:528–538
42. Carta AR (2013) PPAR-γ: therapeutic prospects in Parkinson’s disease. Curr Drug Targets 14:743–751
43. Zhang H, Tang Y, Zhang Y, Zhang S, Qu J, Wang X, Kong R, Han C, Liu Z (2015) Fucoxanthin: a promising medicinal and nutritional ingredient. Evid Based Complement Altern Med. doi:10.1155/2015/723515